Fetal minoxidil syndrome

Fetal minoxidil syndrome is a rare congenital condition caused by prenatal exposure to minoxidil, a potent vasodilator medication used to treat severe hypertension. When taken by the mother during pregnancy, minoxidil can cross the placenta and affect fetal development, leading to a characteristic pattern of birth defects. This condition is classified among teratogenic syndromes and is not inherited genetically but rather results from the direct toxic effects of the drug on the developing fetus. The hallmark feature of fetal minoxidil syndrome is excessive body hair (hypertrichosis), which reflects the well-known hair-growth-promoting properties of minoxidil. Affected newborns may present with generalized hypertrichosis, coarse facial features, and craniofacial abnormalities. Additional reported features include transient cardiovascular anomalies, broad nasal bridge, short nose, and limb anomalies. Some cases have also described developmental delay and growth restriction, though the full spectrum of manifestations can vary depending on the timing, dose, and duration of maternal exposure during pregnancy. There is no specific treatment for fetal minoxidil syndrome. Management is supportive and symptom-based, addressing individual clinical features as they arise. The hypertrichosis typically improves or resolves spontaneously after birth once the drug is cleared from the infant's system. Prevention is the most important strategy, and minoxidil use is generally contraindicated during pregnancy. Women of childbearing age who require antihypertensive therapy should be counseled about the teratogenic risks and offered safer alternative medications.

Common questions about Fetal minoxidil syndrome